Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

In patients (pts) with NSCLC, the efficacy of atezo (anti-PDL1) correlates with PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC). We further examined the association between tumor mutation load (ML) and efficacy of atezo in pts with NSCLC. Pretreatment tumor specimens from 454 2L+ NSCLC pts treated on three Ph 2 trials of atezo monotherapy (POPLAR, a trial comparing atezo vs docetaxel (doc); BIRCH and FIR, single-arm...